clinical trial – Page 2

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials

By MedXY 09/25/2025

Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.

Respiratory Specialties

MACRO Trial Insights: Endoscopic Sinus Surgery Outperforms Clarithromycin in Chronic Rhinosinusitis Management

By MedXY 09/21/2025

The MACRO trial demonstrates that endoscopic sinus surgery significantly improves quality of life in adults with chronic rhinosinusitis, while long-term low-dose clarithromycin shows no added benefit over placebo.

Clinical Updates Infectious Diseases news Respiratory Specialties

Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial

By MedXY 09/21/2025

The endTB-Q trial assessed the efficacy and safety of a shortened BDLC regimen versus WHO standard care in rifampicin-resistant and fluoroquinolone-resistant tuberculosis, finding BDLC non-inferior in mITT but overall not non-inferior, highlighting the need for longer, strengthened treatments.

Neurology news Specialties

Candesartan 16 mg Shows Promise for Episodic Migraine Prevention: Results from a Robust Phase 2 Randomised Trial

By MedXY 09/21/2025

A multi-center, triple-blind phase 2 trial demonstrates that daily candesartan 16 mg significantly reduces migraine days in episodic migraine patients, with tolerable safety profiles, supporting its role as an effective preventive option.

news Oncology Specialties

Dual Immune Checkpoint Blockade Fails to Improve Outcomes in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007 Phase II Study Results

By MedXY 09/21/2025

The NRG Oncology BN007 trial found that combining ipilimumab with nivolumab did not improve progression-free survival compared to temozolomide in patients with newly diagnosed MGMT-unmethylated glioblastoma, leading to early closure of the study before phase III.

Clinical Updates Gastroenterology Internal Medicine news Specialties

Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial

By MedXY 09/20/2025

The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and diabetic populations.

Clinical Updates Oncology

Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

By MedXY 09/20/2025

The NuTide:121 phase III trial compared NUC-1031/cisplatin to gemcitabine/cisplatin in treatment-naïve advanced biliary tract cancer but was terminated early due to lack of survival benefit and increased liver toxicity with NUC-1031.

Clinical Updates Critical Care Emergency Medicine Neurology Specialties

Reevaluating Early Blood Pressure Targets in Acute Spinal Cord Injury: Insights from a Multicenter Randomized Trial

By MedXY 09/20/2025

A recent randomized clinical trial comparing augmented to conventional blood pressure targets in acute spinal cord injury found no improvement in 6-month neurological outcomes, challenging current practices and highlighting risks of higher blood pressure management.

Clinical Updates Diabetes & Endocrinology news Specialties

Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial

By MedXY 09/18/2025

This phase III trial showed that adding lobeglitazone to metformin and sitagliptin significantly improves glycaemic control and insulin sensitivity with favorable safety over 52 weeks in Korean patients with type 2 diabetes inadequately controlled by dual therapy.

Diabetes & Endocrinology news Specialties

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

By MedXY 09/17/2025

Oral semaglutide 25 mg once daily significantly reduces body weight versus placebo and improves physical function in adults with overweight or obesity, offering an alternative to injectable formulations.

Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Hydroxytyrosol Supplementation Enhances Antioxidant and Anti-Inflammatory Status in Overweight Prediabetic Adults: Insights from a Randomized Controlled Trial

By MedXY 09/17/2025

A 16-week randomized trial demonstrates that daily hydroxytyrosol supplementation significantly reduces oxidative stress and inflammatory markers in overweight individuals with prediabetes, highlighting its potential in preventing aging-related diseases.

Clinical Updates OB/GYN & Women's Health Oncology Specialties

Innovative Combination Therapy in Recurrent Advanced Endometrial Cancer: Insights from the ENDOLA Phase I/II Trial

By MedXY 09/16/2025

The ENDOLA trial explored olaparib with metronomic cyclophosphamide and metformin, demonstrating a favorable safety profile and promising efficacy in heavily pretreated recurrent endometrial cancer patients, highlighting molecular subtype-dependent responses.

OB/GYN & Women's Health Oncology Specialties

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

By MedXY 09/16/2025

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm, highlighting the need for alternative therapeutic strategies.

Clinical Updates news Oncology Specialties

Oral Metformin in Non-Muscle-Invasive Bladder Cancer: Insights from a Phase II Marker Lesion Study

By MedXY 09/15/2025

A phase II trial assessing oral metformin for low-grade non-muscle-invasive bladder cancer (NMIBC) found minimal antitumor activity and no significant mechanistic changes, challenging metformin’s role as an intravesical therapeutic agent in this context.

AI Neurology news Specialties

Evaluating AI-Enhanced EMG Reporting: Insights from a Randomized Controlled Trial

By MedXY 09/14/2025

An RCT evaluated an AI-assisted framework for electrodiagnostic report interpretation, finding no significant improvement over standard physician reporting but highlighting potential workflow benefits for routine cases.

Clinical Updates General Surgery Oncology Radiology Specialties

Preoperative versus Postoperative Stereotactic Radiation Therapy for Brain Metastases: Safety, Feasibility, and Efficiency Insights from a Phase 3 Randomized Trial

By MedXY 09/13/2025

A phase 3 randomized trial demonstrates that preoperative stereotactic radiation therapy (SRT) for brain metastases offers comparable safety and reduced treatment duration compared to postoperative SRT, potentially improving patient care logistics.

Clinical Updates Oncology Specialties

High-Dose Aumolertinib Demonstrates Promising Efficacy in Untreated EGFR-Mutant NSCLC with Brain Metastases: Insights from the ACHIEVE Phase 2 Trial

By MedXY 09/11/2025

The ACHIEVE Phase 2 trial reveals that high-dose aumolertinib offers significant intracranial and systemic control with a manageable safety profile in patients with untreated EGFR-mutant NSCLC and brain metastases, highlighting its therapeutic potential.

Anesthesiology OB/GYN & Women's Health Specialties

Transcutaneous Auricular Vagus Nerve Stimulation: A Novel Approach to Managing Postpartum Uterine Contraction Pain after Cesarean Delivery

By MedXY 09/11/2025

A randomized clinical trial shows that transcutaneous auricular vagus nerve stimulation significantly reduces postpartum uterine contraction pain, incisional pain, anxiety, and depression, enhancing recovery and sleep quality in cesarean delivery patients.

news Psychiatry Specialties

Esketamine Monotherapy for Treatment-Resistant Depression: A New Therapeutic Frontier

By MedXY 09/11/2025

A phase 4 randomized trial demonstrates that esketamine nasal spray monotherapy significantly reduces depressive symptoms in adults with treatment-resistant depression, offering a promising alternative to oral antidepressants.

Neurology Specialties

Evaluating Intra-Arterial Tenecteplase Post-Thrombectomy in Large Vessel Occlusion Stroke: Safety and Early Efficacy from a Dose-Escalation Randomized Trial

By MedXY 09/11/2025

Adjunctive intra-arterial tenecteplase after successful reperfusion in anterior circulation large vessel occlusion stroke demonstrates an acceptable safety profile at low doses, supporting further investigation into its therapeutic potential.